


Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development in Korea

09 January 2025 | News

Samsung Biologics to offer antibody drug conjugate (ADC) services at new dedicated facility



South Korea-based Samsung Biologics, a global contract development and manufacturing organisation (CDMO), has announced to extend collaboration with LigaChem Biosciences to provide antibody-drug conjugate (ADC) services.

Samsung Biologics will support a series of LigaChem Biosciences' ADC programmes at Samsung Biologics' new dedicated ADC facility. The two companies have already been collaborating on ADC programmes for the treatment of solid tumours. LigaChem Biosciences is a biotech pioneering research and development of ADC candidates.

"The latest collaboration will further strengthen Samsung Biologics' capabilities across all stages of ADC development and manufacturing as part of our commitment to deliver safe and high-quality therapeutics to patients," said John Rim, CEO and President of Samsung Biologics. "We look forward to supporting our clients' innovative ADC pipelines, ensuring the highest quality and timelines are met."

"This collaboration with Samsung Biologics will be an important step toward strengthening the supply chain of high-quality ADC drugs and enhancing the competitiveness of both companies in the global ADC market," said Yong-Zu Kim, LCB's President and CEO. "By leveraging Samsung Biologics' extensive experience as a CDMO, we will accelerate the development of our pipeline and quickly provide innovative ADC treatments to patients".

Samsung Biologics' ADC facility is a segregated suite, equipped with a 500-liter reactor, supporting the development and manufacture of ADC therapies. Building on the company's track record of expertise in large-scale antibody manufacturing and process engineering, Samsung Biologics' ADC service scope spans late discovery to development and conjugation.

Samsung Biologics has also been making active investments through the Samsung Life Science Fund in biotech companies

pioneering ADC linker technologies, toolbox, and protein engineering.